Orion Oyj Valuation
Is 0M2N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0M2N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0M2N (€44.05) is trading below our estimate of fair value (€52.39)
Significantly Below Fair Value: 0M2N is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0M2N?
Key metric: As 0M2N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0M2N's PE Ratio? | |
|---|---|
| PE Ratio | 18.8x |
| Earnings | €331.70m |
| Market Cap | €6.22b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.4x |
| Enterprise Value/EBITDA | 14.8x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does 0M2N's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25x | ||
HIK Hikma Pharmaceuticals | 17.8x | 11.2% | UK£4.0b |
GSK GSK | 21.3x | 22.4% | UK£53.5b |
AZN AstraZeneca | 29.8x | 18.0% | UK£153.7b |
ANCR Animalcare Group | 30.9x | 15.8% | UK£143.1m |
0M2N Orion Oyj | 18.8x | 9.3% | €6.2b |
Price-To-Earnings vs Peers: 0M2N is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (25x).
Price to Earnings Ratio vs Industry
How does 0M2N's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0M2N is good value based on its Price-To-Earnings Ratio (18.8x) compared to the European Pharmaceuticals industry average (20.7x).
Price to Earnings Ratio vs Fair Ratio
What is 0M2N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0M2N's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Formycon
€820.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€46.50
7D
-3.8%
1Y
-26.2%
hVIVO
UK£172.8m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.25
7D
-10.9%
1Y
39.6%
Dermapharm Holding
€1.9b
Manufactures and sells off-patent branded pharmaceutical products in Germany.
0A5J
€34.35
7D
7.7%
1Y
-14.5%